摘要
目的:评价奥氮平合并舒肝解郁胶囊对精神分裂症的疗效及安全性。方法:采用随机双盲方法,将57例精神分裂症患者分为研究组和对照组。研究组在奥氮平有效治疗量的基础上加用舒肝解郁胶囊1.44g/d,对照组单用奥氮平治疗,在治疗前及治疗后2、4、6、8周用PANSS量表及TESS量表评定其疗效及不良反应。结果:研究组从第2周起PANSS量表评分与治疗前相比明显降低,对照组从第4周起PANSS量表评分与治疗前相比明显降低,从第2周起研究组的阴性症状分量表评分显著低于对照组(p<0.01),整个治疗过程中2组的阳性症状分量表和一般精神病理症状分量表的评分差异无统计学意义;研究组奥氮平的临床用量小于对照组(p<0.01)。结论:奥氮平合并舒肝解郁胶囊对精神分裂症阴性症状的改善方面有确切疗效,并可减少奥氮平的药物剂量。
Objective：To evaluate the efficacy and safety of Olanzapine combined Shuganjieyu capsule in the treatment of schizophrenia. Methods： Fifty-seven patients with schizophrenia were randomly divided into two groups： Olanzapine combined Shuganjieyu capsule for the study group （n =29） and the Olanzapine for the control group （n=28）, before treatment and after treatment （2,4,6,8） weekend, used positive and negative symptom scale （PANSS） and treatment emergent symptoms scale （TESS） to evaluate the efficacy and side effects. Results：The second week of the study group the total score, positive and negative symptoms, general pathology was significantly lower than before treatment, that in the control group at 4 weeks onset. The study group score of negative symptoms was significantly lower than the control group after 2 weeks. The positive symptoms and general psychopathology symptoms score of the two groups have no difference through all the treatment process. The use of Olanzapine dose in the study group was significantly lower than the control group.Conclusions：Olanzapine combined Shuganjieyu capsule for schizophrenia have a rapid onset, good efficacy and few side effects, and reduce the dose of Olanzapine.
出处
《中国伤残医学》
2013年第3期31-33,共3页
Chinese Journal of Trauma and Disability Medicine
